U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Gartlehner G, Hansen RA, Thieda P, et al. Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jan. (Comparative Effectiveness Reviews, No. 7.)

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression

Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression [Internet].

Show details

Appendix HMeta-analyses of Discontinuation Rates

Discontinuation Rates

Background

Presented in this appendix are relative risk meta-analyses that compare selective serotonin reuptake inhibitors (SSRIs) with individual drugs with respect to discontinuation. The specific comparisons with SSRIs are shown below: bupropion, duloxetine, mirtazapine; nefazodone; trazodone, and venlafaxine The first six figures are for overall discontinuation. The two sets of figures following those are for discontinuation specifically for adverse events and then for discontinuation for lack of efficacy. All are random effects models.

Relative Risk of Overall Discontinuation

Figure H-1. Bupripion vs. SSRIs.

Figure H-1. Bupripion vs. SSRIs

Figure H-2. Duloxetine vs. SSRIs.

Figure H-2. Duloxetine vs. SSRIs

Figure H-3. Mirtazapine vs. SSRIs.

Figure H-3. Mirtazapine vs. SSRIs

Figure H-4. Nefazodone vs. SSRIs.

Figure H-4. Nefazodone vs. SSRIs

Figure H-5. Trazadone vs. SSRIs.

Figure H-5. Trazadone vs. SSRIs

Figure H-6. Venlafaxine vs. SSRIs.

Figure H-6. Venlafaxine vs. SSRIs

Relative Risk of Discontinuation because of Adverse Events

Figure H-7. Bupropion vs. SSRIs: Adverse Events.

Figure H-7. Bupropion vs. SSRIs: Adverse Events

Figure H-8. Duloxetine vs. SSRIs: Adverse Events Only.

Figure H-8. Duloxetine vs. SSRIs: Adverse Events Only

Figure H-9. Mirtzapine vs SSRIs: Adverse Events Only.

Figure H-9. Mirtzapine vs SSRIs: Adverse Events Only

Figure H-10. Nefazodone vs SSRIs: Adverse Events Only.

Figure H-10. Nefazodone vs SSRIs: Adverse Events Only

Figure H-11. Trazodone vs SSRIs: Adverse Events Only.

Figure H-11. Trazodone vs SSRIs: Adverse Events Only

Figure H-12. Venlafaxine vs SSRIs: Adverse Events Only.

Figure H-12. Venlafaxine vs SSRIs: Adverse Events Only

Relative Risk of Discontinuation because of Lack of Efficacy

Figure H-13. Bupropion vs. SSRIs: Lack of Efficacy.

Figure H-13. Bupropion vs. SSRIs: Lack of Efficacy

Figure H-14. Mirtzazpine vs. SSRIs: Lack of Efficacy.

Figure H-14. Mirtzazpine vs. SSRIs: Lack of Efficacy

Figure H-15. Nefazodone vs SSRIs: Lack of Efficacy.

Figure H-15. Nefazodone vs SSRIs: Lack of Efficacy

Figure H-16. Venlaxafine vs SSRIs: Lack of Efficacy.

Figure H-16. Venlaxafine vs SSRIs: Lack of Efficacy

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (11M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...